Why does glucagon receptor activation help with weight loss if glucagon raises blood sugar?

Glucagon receptor activation in the liver increases fatty acid oxidation and raises basal metabolic rate. The co-activation of GLP-1 receptors counteracts the hyperglycaemic effect by stimulating insulin secretion, resulting in a net increase in energy expenditure without harmful glucose elevation.

How does retatrutide compare to tirzepatide in phase 2 data?

Phase 2 data for retatrutide showed higher average weight reduction (up to 24.2% at 12mg) compared to tirzepatide phase 2 data, though direct head-to-head comparisons have not been published. Phase 3 trials are ongoing.

New

Retatrutide

Name: Retatrutide
Price: 60 USD
Availability: InStock

Triple GLP-1, GIP, and glucagon receptor agonist. Phase 2 data reported up to 24.2% body weight reduction at 12mg weekly dose over 48 weeks.

Fat LossGH Boost

● In Stock

Select Variant

Quantity (vials)

Buy more, save more

—

1+ vials

−5%

3+ vials

−10%

5+ vials

−20%

10+ vials

Total Price

$60

For research & laboratory use only. Not for human consumption.

Half-Life

6 days

Administration Route

Subcutaneous injection

Triple Receptor Agonist

Targets GLP-1, GIP & glucagon for maximum metabolic effect

24.2% Body Weight Loss

Exceeds semaglutide & tirzepatide in Phase 2 head-to-head

Liver Fat Reduction

Glucagon receptor activation directly drives hepatic lipolysis

Effect Profile

Based on primary research mechanisms

Fat Loss

Hunger Control

Metabolic Health

Energy

Effect Timeline

Start

Appetite suppression kicks in; gastric emptying slows

Week 4

4–6% weight loss; liver fat begins reducing

Week 8

Visceral fat visibly reduced; energy expenditure elevated

Week 16

12–16% weight loss; metabolic rate measurably increased

Start — Week 1–2

Appetite suppression kicks in; gastric emptying slows

Week 4

4–6% weight loss; liver fat begins reducing

Week 8

Visceral fat visibly reduced; energy expenditure elevated

Week 16

12–16% weight loss; metabolic rate measurably increased

Mechanism of Action

Retatrutide simultaneously activates three incretin and glucagon receptors. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation enhances insulin sensitivity and adipose tissue metabolism. Glucagon receptor activation increases energy expenditure by stimulating hepatic fatty acid oxidation and thermogenesis. The triple mechanism targets both energy intake and energy expenditure, producing metabolic effects beyond those achievable with single or dual receptor agonists.